Griffith University

Aaron Lock

Name: Aaron Lock
Position: Research Assistant
Research Area: Cancer Drug Discovery
Qualifications: B. App. Sci (Lab Medicine) (Hons)

Biography: As a member of the Cancer Therapeutics initiative, Aaron is involved in the development and optimisation of a range of isolated target molecule- and cell-based in vitro bioassays relating to specific cancer types. These bioassays are used to screen a library of >250, 000 drug-like compounds in order to identify potential cancer therapeutics. Following on from this, Aaron also investigates downstream targets for specific cancer signalling pathways, as a means of identifying drug inhibitor modes of action.

Discovery Biology


Kaemmerer E, Rodriguez Garzon T, Lock A, Lovitt C and Avery VM. Innovative in vitro models for breast cancer drug discovery. Drug Discovery Today: Disease Models. [Invited review] 2017 March 18; 21: 11-16.

Stevenson G, Yong S, Fechner G, Neve J, Lock A and Avery VM. Solid-Phase Synthesis of Biotin-S-Farnesyl-L-Cysteine, a surrogate substrate for Isoprenylcysteine Carboxylmethyltransferase (ICMT). Bioorg Medicinal Chemistry Letters. 2013 Oct 15; 23(20): 5671-5673.


2019: Brisbane Immunotherapy, Brisbane, Australia

2019: SIMM Symposium, Brisbane, Australia

2019: Drug Discovery & Development in Oncology Symposium, Melbourne, Australia

2018: Advances in Cancer Drug Discovery and Development Symposium, Melbourne, Australia

2016: Brisbane Cancer Conference, Brisbane, Australia

2015: Queensland EMT Symposium, Brisbane, Australia

2015: Brisbane Cancer Conference, Brisbane, Australia

2014: Brisbane Cell and Developmental Biology Meeting, Brisbane, Australia

2013: 25th Lorne Cancer Conference, Lorne, Australia Poster: Small molecule inhibitors of ICMT as potential cancer therapeutics.

2012: 24th Lorne Cancer Conference, Lorne, Australia


2020: GRIDD RICE Values Award

2018: Cancer Therapeutics CRC (CTx) Gold Award

2013: Griffith University Research Health and Safety Initiative Award